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Summary We have previously show-n that epidermal growxth factor (EGF) enhances the in iitro and in ribo
sensitivitv of human ovarian carcinoma 2008 cells to cisplatin. EGF wxas found to enhance selectixely the in
1iio toxicity of cisplatin to 2008 cell xenografts wxithout altenng the toxicity of cisplatin to non-malignant
target tissues such as the kidnev or bone marrow. We now- show- that recombinant human EGF (rhEGF)
enhances the cisplatin sensitivity of cell lines representatixe of many other types of malignancies in addition to
oxarian carcinoma, including cancers of the head and neck. cervix. colon. pancreas and prostate. as "A-ell as
non-small-cell carcinoma of the lung. In addition. rhEGF x-as found to sensitise cells to other platinum-
contaiming drugs and sexeral other classes of chemotherapeutic agents. rhEGF sensitised 2008 cells not onlv to
cisplatin. but also to carboplatin and tetraplatin. as well as taxol. melphalan and 5-fluorouracil. We conclude
that modulation of drug sensitiVitv bv rhEGF is observed in cell lines representatixe of manv human
malignancies and for multiple classes of chemotherapeutic agents. indicating that it alters one or more
components of the cellular damage response that are both common betxween cell lines and classes of drugs and
fundamental to survixval.
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We have previously shown that a brief exposure to EGF
enhances the cvtotoxicity of cisplatin and causes a long-
lasting change in morpholog- in the absence of any
mitogenic effect in two human ovarian carcinoma cell lines
designated 2008 and COLO 316 (Chn'sten et al.. 1990).
Exposure of human ovarian carcinoma cells to 10 nm EGF
for 1 h and then concurrently to EGF and cisplatin for
another hour increased the sensitivitv to cisplatin 2- to 4-
fold. as quantitated by the ratio of the ICro values using a
clonogenic assay. Exposure of 2008 cells to EGF and cisp-
latin concurrently for 1 h induced the same degree of sen-
sitisation to cisplatin. Time course experiments showed that
sensitivity to cisplatin was maximal 3 h after a 1 h exposure
to 10 n-m EGF. and that the effect had largely disappeared bv
24 h. The EGF-induced increase in sensitivitv of 2008 cells to
cisplatin was not dependent on new protein synthesis:
pretreatment with cvcloheximide. at a concentration sufficient
to inhibit protein synthesis by 90%. did not block the effect.
Cisplatin sensitivity was found to be dependent on both the
EGF concentration and the EGF receptor number in mouse
fibroblasts expressing the human EGF receptor after trans-
fection with a pBPV plasmid construct containing the human
EGF receptor gene under control of the transferrin receptor
3'-inducible regulator. Although the degree of EGF-induced
enhancement of sensitivity to cisplatin was only in the range
of 2- to 4-fold. this represents a potentially clinically
significant effect since patients with acquired cisplatin resis-
tance have relatively low levels of resistance (Inoue et al..
1985: Wilson et al.. 1987: Wolf et al.. 1987) that can be
partially overcome by increasing cisplatin dose by 2-fold
(Howell et al.. 1987: Kaye et al.. 1992).
We now show that EGF enhances the in vitro toxicity of
EGF against cell lines representative of a broad range of
clinically important cancers. and that. in addition to enhanc-
ing cisplatin toxicity. EGF also enhances the toxicity of a
number of chnically important chemotherapeutic agents.
These findings establish that modulation of drug sensitivity
by rhEGF is observed in many different types of cells and for
multiple classes of chemotherapeutic agents. indicating that it
alters one or more components of the cellular damage res-
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ponse that are both common to all cell lines and classes of
drugs and fundamental to survival.
Methods
Drugs
Cisplatin and carboplatin (clinical formulation) wxere ob-
tained from Bristol-My-ers Squibb (Pnrnceton. NJ. USA).
Desiccated cisplatin Nvas reconstituted w-ith sterile water at a
concentration of 1 mg ml-'. Deferoxamine mesy-late was
obtained from Ciba-Geigy. Basle. Sw-itzerland. rhEGF.
murine EGF. melphalan. doxorubicin. 4-hydroperoxycyclo-
phosphamide. taxol and 5-fluorouracil wvere obtained from
Sigma (St Louis. MO. USA). Mouse EGF w-as used to
determine the effect of EGF on drug sensitivity in C127
mouse fibroblasts. Mouse EGF and human EGF have been
shown to be 70/0 homologous (Saggi et al.. 1992). In a
number of different model syvstems. the biological effects of
mouse EGF and human EGF have been show-n to be iden-
tical (Cohen and Carpenter. 1975: Carpenter. 1979: Carp-
enter and Zendegui. 1986).
Cell Lines
The following cell lines w-ere obtained from the Amenrcan
Type Culture Collection or directly from the depositor of the
cell line: A549 non-small-cell lunz cancer (Lieber et al..
1976). NCI-H596 adenosquamous lung cancer (Banks-
Schlegel et al.. 1985). UMC 31 small-cell lung cancer cells
(Graziano et al.. 1991). GLC4 small-cell lung cancer cells
(Zijlstra et al.. 1987). UMSCCIOb head and neck cancer cells
(Krause et al.. 1981). UMSCClOb Pt-6S cisplatin-resistant
head and neck cancer cells (Nakata et al.. 1994). 5637 blad-
der cancer cells (Fogh et al.. 1977). MIA PaCa-2 pancreatic
cancer cells (Yunis et al.. 1977). Du 145 prostate cancer
(Mickey. 1977: Connollv and Rose. 1989). COLO 205 colon
cancer (Semple et al.. 1978). KB-3-1 cervix cancer (Akiyama
et al.. 1985). SiHa cervix cancer (Friedl et al. 1970). A431
epidermoid carcinoma of the skin (Giard et al.. 1973). T-289
melanoma cells (Taetle et al.. 1987). Human ovarian car-
cinoma 2008 cells (DiSaia et al.. 1972) were used to deter-
mine the effect of rhEGF on the toxicits of different
chemotherapeutic agents. 2008 cells have been shown to exp-EGF moduation f dsplain oxicity
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ress 1.6 x 10 EGF receptors per cell with a dissociation
constant (Kd) of 2.4 nm (Christen et al.. 1990). In this cell
line, the EGF receptor has been shown to be functional as
assessed bv demonstrating down-regulation of the EGF
receptor upon binding of EGF (Christen et al.. 1990). The
10-fold cisplatin-resistant subline 2008 C13*5.25 was found
to express 5.8 x 10' EGF receptors per cell (Christen et al..
1990). Transfected C127 mouse fibroblasts were used to dem-
onstrate that. within a given cell line. the effect of EGF on
cisplatin sensitivitx was dependent on the EGF receptor
number. C1217 cells were stably transfected with a pBPV
plasmid construct containing the human EGF receptor gene
under the control of the transfemrn receptor 3'-inducible
regulator (Christen et al.. 1990). To induce the EGF recep-
tor. transfected cells were treated with lOjm deferoxamine
mesvlate and 25 jig ml-1 transferrin for 60 h. Transfected
C127 fibroblasts grown in medium supplemented with fetal
calf serum expressed 1.8 x 10' EGF receptors. including
murine and human receptors. After treatment with deferox-
amine. transfected C127 cells expressed 4.5 x I0W receptors
per cell. including murine and human receptors (Christen et
al.. 1990). Cells were grown in one of the following types of
medium: RPMI-1640. RPMI-1640 plus HITES buffer. Dul-
becco's Modified Eagle medium (DMEM) low glucose or
DMEM high glucose. All types of media were supplemented
with 5-10% heat-inactivated fetal calf serum and 2 mm
glutamine: cells were grown at 37C in a humidified 5%
carbon dioxide atmosphere. Each cell line was tested with
triplicate cultures for each data point.
Colony forming assay on plastic dishes
Colonv-forming assays w-ere performed by seeding 250 cells
per 60 mm tissue culture plastic dish. Corning Glass Works
(Corninz. NY. USA). Cells w-ere allowed to attach to the
culture dishes overnight and w-ere then treated with rhEGF
and cisplatin concurrently for 1 h. Cell clusters containing
more than 50 cells were scored as a colons after 10 davs of
incubation in humidified 5°, carbon dioxide at 37C.
Coloni-forming assa'i in soft agar
Cells were trypsinised and resuspended in complete medium.
aliquoted at 2 ml containing 10 000 cells per ml. and exposed
to cisplatin and rhEGF concurrently for 1 h. The drug-
containing medium was removed and cells were resuspended
in 5 ml of complete medium containing 0.36°o low melting
temperature agarose at 37°C. The cell suspension was mixed
well and then aliquoted at I ml per dish in triplicate onto
prepared 35 mm dishes containing a basement layer of
solidified 10o agarose. The cell-containing laver was allowed
to solidify at 4'C for 10 mmn. and the dishes were incubated
at 37°C in humidified 0oo carbon dioxide. Colonies greater
than 125Ljm were counted after 5 days.
Results
Effect of rhEGF on cisplatin toxicity
The effect of rhEGF on cellular sensitivity to the cy-totoxic
effect of cisplatin was determined for a -ariets of cell lines
representative of clinically- important types of human malig-
nancies. To determine the effect of rhEGF on cisplatin tox-
icit. cells were exposed to rhEGF and cisplatin concurrently
for I h. The concentration of rhEGF was fixed at 10 nm. and
the concentration of cisplatin was varied to generate a sur-
vival curve spanninz 2 logs of tumour cell kill. As an exam-
ple. Figure I shows the effect of rhEGF on cisplatin toxicity
in UMSCClOb head and neck cancer cells. In this cell line.
rhEGF enhanced cisplatin toxicits by 3.8-fold. as quantitated
by the ratio of the IC,, values. This ratio is referred to as the
dose-modifyvinz factor.
Table I summanses the effect of rhEGF on the cisplatin
sensitivity of all of the cell lines tested. rhEGF was found to
enhance cisplatin toxicity in a number of cell lines from
different tissues of origin. including cancers of the head and
neck. cervical epithelium. ovary. pancreas. prostate and colon
as well as non-small-cell cancer of the lung (type II alveolar
epithelial cells). In these cell lines. rhEGF enhanced cisplatin
toxicity by 1.4- to 3.8-fold. The highest degree of chemosen-
sitisation by EGF was observed in squamous cancer cells.
such as those from carcinomas of the head and neck. cervix
and lung. rhEGF failed to increase the cytotoxicitv of cis-
platin to cell lines representative of melanoma and small-cell
lung cancer.
To demonstrate that. within a given cell line. the modul-
ating effect of EGF on cisplatin was dependent on the EGF
receptor number. we determined the effect of EGF on cis-
platin sensitivity in C127 fibroblasts stably transfected with a
plasmid construct containing the human EGF receptor gene
under the control of the transferrn receptor 3'-inducible
regulator (Christen et al.. 199%). Up-regulation of the EGF
receptor by 2.5-fold. following deferoxamine treatment.
markedly enhanced the effect of EGF on cisplatin sensitivity;
(Table I).
Morphological changes induced by rhEGF
In addition to enhancing sensitivity to cisplatin. and despite
the lack of effect on colony growth. a 1 h exposure to rhEGF
had marked effects on the morphology of those cell lines that
exhibited chemosensitisation by rhEGF. Figure 2 shows the
morphological changes induced by EGF in UMSCClOb head
and neck cancer cells. At the macroscopic levels. colonies
formed by these cell lines 10 days after exposure to rhEGF
were much larger and stained less intensely with Giemsa. At
the microscopic level. colonies formed from untreated cells
consisted of tightly packed cells. whereas colonies arising
after treatment with rhEGF consisted of widelv scattered
cells. of which most had formed prominent dendritic pro-
cesses. It was of particular interest that in those cell lines in
which rhEGF failed to enhance cisplatin toxicity rhEGF did
not induce these morphological changes. EGF had no
significant effect on the average number of cells per colony or
on the number of colonies formed by the cell lines referenced
in Table I (data not shown).
Effect ofrhEGF on the toxicity ofother chemotherapeutic
agents
Table II summarises the effect of EGF on the sensitivity of
2008 cells to several platinum compounds and other com-
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Figure I Effect of rhEGF on the sensitivity of UMSCC-lOb
head and neck cancer cells to cisplatin. Dose-response curxes
were determined bv colonv-forming assay. Cells were treated
concurrently-with 10 n-M rhEGF and increasing concentrations of
cisplatin. Open circles (0). control cells treated with cisplatin
alone; closed circles (0). cells treated with rhEGF plus cisplatin
for 1 h concurrently. Left: Parental UMSCC-lOb cells. Right:
Cisplatin-resistant UMSCC-1Ob Pt-6S cells. Data points represent
means ± s.d. of three expenrments.EGF modulation dcsplatintxicity
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Table I Effect of rhEGF on cisplatn sensitivity in different cell lines
EGF receptors IC50 (ILm) in absence ICm (pm) in Dose-modifting
Type ofcell line Name ofcell line per cells ofEGP presence ofEGFP factor? P-value'
Head and neck cancer UMSCClOb 6.9 ± 0.6 1.8 ± 0.5 3.8 ± 0.2 <0.001
Head and neck cancer UMSCCIOb Pt6S 9.0 1.4 5.1 0.5 1.8 ±0.2 0.010
(cisplatin-resistant)
Non-small-cell lung cancer A549 14.5 ± 3.5 7.3 ± 0.5 2.0 ± 0.6 0.024
Non-small-cell lung cancer NCI-H596 1.3 0.2 0.7+0.2 1.9+0.3 0.021
Ovarian carcinoma 2008 1.6 x I0O 2.5 ± 0.2 0.9 ± 0.1 2.8 ± 0.1 <0.001
Cervix cancer KB-3-1 2.0 x i0W 9.7 0.4 4.8 ± 0.4 2.0 0.2 <0.001
Cervix cancer SiHa 1.1 x 10 4.8 ±0.6 1.5 ± 0.2 3.2 ± 0.4 <0.001
Colon cancer RKO 27.6 ± 4.6 16.5 ± 5.0 1.7 ± 0.6 0.047
Prostate cancer Du 145 5.9 x 106 8.5 1.2 5.5 0.1 1.5 0.4 0.012
Pancreatic cancer MIA PaCa-2 7.7 ± 0.4 5.5 ± 0.1 1.4 0.1 <0.001
Breast cancer MCF-7 3.0 x 103 3.8 ± 0.2 3.7 ± 0.5 1.0 ± 0.2 0.764
Small-cell lung cancer GLC4 12.2 ± 2.7 15.1 ± 3.3 0.8 ± 0.3 0.304
Small-cell lung cancer UMC31 5.4 ± 1.5 6.8 ± 1.3 0.8 ± 0.3 0.289
Malignant melanoma T-289 2.0 ± 0.4 2.5 ± 0.5 0.8 ± 0.4 0.368
Fibroblasts transfected With EGF C127 1.8 x I0- 3.2 ± 0.5 1.4 ± 0.3 2.3 ± 0.4 0.006
receptor gene
Fibroblasts transfected with EGF C127 4.5 x I0- 3.0 ± 0.4 0.7 ± 0.4 3.8 ± 0.5 0.002
receptor gene treated with
deferoxarriine
'Dose response curves weredetermined bycolony-forming assay (mean ± s.d., n = 3).FThedose-modifying factor represents the ratio oftheIC50
values in control and rhEGF-treated cells (mean ± s.d., n = 3). 'Comparison of the IC5, values in the absence and presence of EGF by unpaired.
two-sided t-test.
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F'tg_e 2 Morphological changes induced by a rhEGF in
UMSCCIOb head and neck cancer cells. Cells were seeded on
plastic dishes and exposed to 1O nM rhEGF for 1 h. Colonies
were inspected by light microscopy after 10 days of incubation.
(a) Untreated control cells showing a dense monolayer of cells
with round nuclei and dense chromatin. (b) EGF-treated cells
showing the formation of prominent dendnrtic processes.
monly used chemotherapeutic agents. In 2008 cells, EGF
induced a significant increase in sensitivity not only to cisp-
latin but also to carboplatin, tetraplatin, taxol and 5-
fluorouracil. EGF also increased the sensitivity of 2008 cells
to melphalan, however the effect did not reach the level of
statistical significance. Interestingly, EGF had no significant
effect on the sensitivity of 2008 cells to doxorubicin and
4-hydroperoxycyclophosphamide.
We have previously established that EGF enhances cisplatin
toxicity against human ovarian carcinoma cells in vitro and in
vivo (Christen et al., 1990, 1994). In order to better unders-
tand the biological importance of our initial observation, we
asked whether, in addition to ovarian cancer, EGF would
also enhance drug sensitivity in other types of cancer, and
whether, in addition to cisplatin, EGF would sensitise cancer
cells to other chemotherapeutic agents.
We now report that rhEGF enhances cisplatin toxicity
against a number of cell lines representative of clinically
important types of malignancies, including cancers of the
head and neck, cervix, ovary, pancreas, prostate and colon as
well as non-small-cell lung cancer. It is interesting to note
that, while rhEGF did not enhance the sensitivity to cisplatin
of all cell lines tested, it did increase the cytotoxicity of
cisplatin against at least some cell lines derived from both
tumours generally considered to be sensitive to cisplatin, such
as ovarian cancer, non-small-cell lung cancer and head and
neck cancer, and some cell lines derived from tumours
usually considered to be clinically resistant to cisplatin, such
as carcinomas of the colon, prostate and pancreas. These
results extend those of Amagase et al. (1989), who reported
that EGF enhanced cisplatin toxicity against a panel of
human tumour cell lines grown as xenografts in athymic
mice. These cell lines included A431 epidermoid carcinoma
cells, KB nasopharynx carcinoma cells, HCT8 colon car-
cinoma cells and a number of different gastric cancer cells,
including the SC-6JCK, KATOIII and MKN45 tumours.
In addition to enhancing the toxicity of cisplatin, and
despite the lack of effect on colony growth, rhEGF caused
marked changes in the morphology of those cell lines that
exhibited chemosensitisation. Interestingly, in those cell lines
in which rhEGF failed to enhance cisplatin toxicity, rhEGF
did not induce morphological changes. It is conceivable that
the changes in morphology, including the formation of
marked dendritic processes, were the result of an EGF-
induced activation of a differentiation program (Christen et
al., 1990). Even though, in our cell lines, sensitisation to
cisplatin by EGF was associated with morphological changes
induced by EGF, these two events represent two distinct
617EGF moduation ofdsplatin bcity
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Table II Effect ofEGF onthesensitivity of2008 ovarian carcinoma cells todifferent chemotherapeutic
agents
IC" in absence and
Cell line Citotoxic agent presence ofEGP Dose-modifuingfactor' P-Yalue'
2008 Cisplatin 2.8 0.9 11M 3.1 ± 0.9 0.027
2008 Carboplatin 120 671LM 1.8 ± 0.4 0.022
2008 Tetraplatin 10 6 lM 1.6 ± 0.1 0.033
2008 5-Fluorouracil 20 11 i1M 1.8 + 0.3 0.022
2008 Taxol 10 7 nM 1.4 0.1 0.003
2008 Melphalan 12 9ALM 1.4 0.4 0.084
2008 Doxorubicin 1.5 1.4giM 1.1± 0.2 0.636
2008 4-Hydroxycvclophosphamide 40 44 M 0.9 ± 0.5 0.634
aDose-responsecurvesweredeternined bycolony-forming assay. Cellswereexposed to EGFand the
cy-totoxic agent concurrently for 1 h. Taxol-treated cells were exposed to taxol with or without EGF for
24 h. thedose-modifying factor represents the ratio ofthe IC, values in control and EGF-treated cells.
Mean ± s.d. of at least three different experiments are shown. cComparison of the ICO values of the
cytotoxic agent in the absence vs presence of EGF by two-sided t-test.
biological effects of EGF. Chemosensitisation by EGF
appears very rapidly and is not dependent on new protein
synthesis (Christen et al., 1990); in contrast, morphological
changes, indicating activation of a differentiation programme.
develop slowly and are dependent on new protein synthesis.
We have previously reported that enhancement of drug
sensitivity by EGF was, within a given cell line, dependent on
the EGF receptor number (Christen et al., 1990). Exper-
iments in mouse fibroblasts transfected with an inducible
construct containing the EGF receptor gene under control of
the transferrin 3'-inducible regulator have established that
increasing the EGF receptor number by 2.5-fold augmented
the abilitv of EGF to enhance sensitivity to cisplatin by
2-fold. This is also in agreement with the results of Amagase
et al. (1989). who found that the degree of EGF sensitisation
was correlated with the EGF receptor number expressed on
the grafted tumour cells. This observation is important in
light of the finding that many solid tumours express a much
higher number of EGF receptors than non-malignant cells of
the same organ (Haley, 1990). Specifically, EGF receptor
overexpression has been documented in different types of
squamous cell cancer, colon cancer and ovarian cancer
(Haley, 1990). Hence these types of cancer would be expected
to exhibit more pronounced enhancement ofcisplatin toxicity
in response to EGF than normal tissues expressing lower
levels of the EGF receptor. Such differential expression of
EGF receptor numbers is an important basis for the poten-
tial selectivity of the rhEGF cisplatin combination.
In addition to enhancing the sensitivity of 2008 human
ovarian carcinoma cells to cisplatin, EGF was also found to
enhance the in vitro toxicity of several other clinically impor-
tant chemotherapeutic agents against 2008 cells. These agents
included drugs with different mechanisms of action, such as
carboplatin, tetraplatin. melphalan, taxol and 5-fluorouracil
(Table II). Amagase et al. (1989) also found that EGF could
selectively enhance the in vivo toxicity of a number of
different chemotherapeutic agents to human tumour xenog-
rafts grown in athymic mice, including 5-fluorouracil,
tegafur, doxorubicin. mitomycin C, cyclophosphamide and
cisplatin. In addition to enhancing chemosensitivity, we have
found that EGF can enhance the toxicity of UV-B radiation
(Christen et al.. 1991) and Kwok and Sutherland (1989) have
reported that EGF can make cells more sensitive to gamma-
radiation.
The fact that EGF enhanced the toxicity of different
chemotherapeutic agents against different types of cell lines
indicates that the biochemical and molecular mechanisms
that mediate this interaction are common to multiple cell
types, and that chemosensitisation by EGF is not dependent
on a specific biochemical pathway found only in one or
another type of differentiated or partially differentiated
cancer cell. It also suggests that the underlying mechanism is
not specific for any molecular target(s), or for the bio-
chemical pharmacology of any one agent. We have inves-
tigated the mechanism by which EGF enhances cisplatin
toxicity in 2008 cells (Christen et al., 1991). EGF had no
effect on the total cellular uptake of cisplatin and formation
of platinum-DNA intrastrand adducts at adjacent guanine-
guanine sequences. EGF did not alter the cytosolic inactiva-
tion of cisplatin by inducing changes in cellular glutathione
or metallothionein levels. However, EGF was found to
impair the removal of guanine-guanine intrastrand cross-
links. After a 24 h repair period. EGF induced a 10%
decrease in the rate of adduct removal. The biological
significance of this small change in the rate of adduct
removal produced by EGF is currently not understood.
Clearly, EGF-induced alterations in DNA repair cannot
account for the observation that EGF enhances the toxicity
of drugs, such as taxol, that kill cells without causing DNA
damage. It may thus be conjectured that, in addition to
altering DNA repair, EGF causes important changes in other
components of the complex cellular response to damage.
Activation of a number of different signal transduction
pathways, in addition to that of the EGF receptor, has been
shown to modulate cisplatin sensitivity. These signalling
events include pathways activated by the tumour necrosis
factor receptor (Isonishi et al., 1992), the bombesin receptor
(Isonishi et al., 1992), protein kinase A (Mann et al., 1991)
and protein kinase C (Isonishi et al., 1990). Thus the concept
is evolving that signal transduction pathways can regulate
some components of the cellular response to drug-induced
damage that are critical to the cell's ability to survive the
insult. Moreover, such cellular damage itself activates a varie-
ty of these same pathways as has been reported for UV-B
radiation, gamma-radiation and alkylating agents (Holbrook
and Fornace, 1991; Devary et al., 1992).
Recent findings have helped to shift the focus of attention
from the classical concept that drug sensitivity is determined
primarily by factors such as drug and target concentration to
the idea that post-receptor events can play a critical role in
whether a cell survives or dies. We are beginning to under-
stand that drug target interactions are not alone responsible
for cell death (Dive and Hickman, 1991). Rather, the
drug-target interaction and its sequelae, which include sig-
nalling events activated by the drug-target interaction, may
act as the trigger for both protective responses and pathways
activating cell death (Dive and Hickman, 1991). Clearly, we
can modulate cellular sensitivity by activating multiple
different kinds of signal transduction pathways. The data
that exist for chemotherapeutic agents, UV-B radiation and
gamma-radiation suggest that the effect may not be at the
level of the interaction with the primary target, but on some
event triggered by this interaction. DNA-damaging agents
clearly cause the activation of a variety of signal transduction
pathways, and it may be that it is primarily on these damage-
induced responses, both protective and destructive, that the
modulator pathways are working.
Abbreviatioa
rhEGF, recombinant human epidermal growth factor: cisplatin
(DDP), cisdiamminedichloroplatinum (II); IC%. dose level resulting
in 50% inhibition of cell survival.EGF modultion cisplatin toxicity
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